What will Jimenez and the new structure bring to Novartis?
This article was originally published in Scrip
Change at the top of Novartis has been on the cards for a while. The company had been expected to separate the roles of chairman and CEO, and Daniel Vasella, who has been at the helm for 14 years, was expected to step aside. These changes are now in place, along with some surprises at the top.
You may also be interested in...
This year has seen many firms facing patent expiries on core revenue generators. The current climate is driving M&A strategies, particularly in emerging markets and often with a focus on branded generics. Abbott has used M&A to propel itself to the top of the Indian market, writes Karen Beynon.
The debate surrounding reform of the US healthcare system dominated headlines throughout 2009. Here are some of the landmark events of the past 12 months.
Pharmaceutical companies are bracing themselves for Japan's next round of drug price cuts, due in April 2010. Faced with shrinking margins at home, Japanese firms are refocusing their efforts on rapidly expanding Asian and stable western markets to prop up their bottom lines. Will Japanese pharma lose its taste for innovation, asks Karen Beynon.